TT-P34
Asset
Improves mitochondrial and lysosomal function through a dual mechanism of action.
- Stage
- Phase 1
- Modality
- Peptide
- Target
- Not known
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3Frontotemporal dementia
Phase 1, teiturtrophics.com, 10 Oct 2026
Huntington's disease
Phase 1, teiturtrophics.com, 10 Oct 2026
Parkinson's disease
Phase 1, teiturtrophics.com, 10 Oct 2026
In the full profile
- Owner and partners1
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.